Development of a genetic test for evaluating 5-year survival of patients with acute myeloid leukemia and myelodysplastic syndrome
- Authors: Glukhanyuk EV1,2
-
Affiliations:
- Ural State Medical Academy, Ekaterinburg, Russia
- Moscow State University named after M.V. Lomonosov, Moscow, Russia
- Issue: Vol 93, No 2 (2012)
- Pages: 351-353
- Section: Transfusiology of the XXI century: problems, goals, future perspectives
- URL: https://ogarev-online.ru/kazanmedj/article/view/2332
- DOI: https://doi.org/10.17816/KMJ2332
- ID: 2332
Cite item
Full Text
Abstract
Aim. To study the mutations in the gene CEBPA - a transcription factor that plays an important role in myeloid differentiation. Methods. Venous blood or bone marrow biopsy specimen samples from 16 patients with acute myeloid leukemia served as the materials for the study. The method of investigation - polymerase chain reaction followed by sequencing. Results. The obtained data was analyzed; the patients are under active surveillance. Since the most common and prognostically meaningful are the combinations of N- and C-terminal mutations, in the case of a «hot spot» detection (the combination of certain mutations) a more feasible test can be developed. Identifying groups of patients with favorable and unfavorable prognosis will dramatically affect the tactics of patient management: its radicalism, aggressiveness and cost of treatment. Conclusion. A small number of examinees does not yet make it possible to establish a statistically significant correlation between specific mutations and prognostic significance, as well as to identify the combinations of most frequent mutations.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
E V Glukhanyuk
Ural State Medical Academy, Ekaterinburg, Russia; Moscow State University named after M.V. Lomonosov, Moscow, Russia
Email: evgengluhanuk@gmail.com
References
- Boissel N., Renneville A., Biggio V. et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype // Blood. - 2005. - Vol. 106. - P. 3618-3620.
- Falini B., Martelli M., Bolli N. et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? // Blood. - 2011. - Vol. 117. - P. 1109-1120.
- Friedman A.D. Transcriptional regulation of granulocyte and monocyte development // Oncogene. - 2002. - Vol. 21. - P. 3377-3390.
- Frohling S., Dohner H. Disruption of C/EBPalpha function in acute myeloid leukaemia // N. Engl. J. Med. - 2004. - Vol. 351. - P. 2370-2372.
- Jaffe E.S., Harris N.L., Stein H. et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. - Lyon, France: IARC, 2001. - 356 p.
- Reckze K., Cammenga L. Molecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemia // Intern. J. of Hematol. - 2010. - Vol. 4. - P. 557-568.
- Taskesen E., Bullinger L., Corbacioglu A. et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity // Blood. - 2011. - Vol. 117. - P. 2469-2475.
- Vardiman J.W., Thiele J., Arber D.A. at al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes // Blood. - 2009. - Vol. 114. - P. 937-951.
- Wouters J., Löwenberg B., Erpelinck-Verschueren C.A.J. et al. Brief report Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome // Blood. - 2009. - Vol. 113 - P. 3088-3091.
Supplementary files
